Endocrine Abstracts

Background: Although gastroenteropancreatic neuroendocrine tumors G3 (GEP-NET G3) and neuroendocrine cancers (GEP-NEC G3) are characterized in histopathological examination by Ki67>20% or >20 mitoses/10HPF their management and prognosis is substantially different. Despite the WHO introduces the novel well-differentiated neuroendocrine tumour of high grade (NET G3) classification in 2017 the clinical management of them is still challenging due to high NET G3 heterogenei...